Lyra Therapeutics

Lyra Therapeutics Shares Rise on Phase 2 Study Success
Marketwatch
Tue, 09/12/23 - 07:12 pm
Lyra Therapeutics
clinical trials
LYR-220
chronic rhinosinusitis
Lyra tackles alcohol use disorder and other mental health conditions
Stat
Thu, 09/2/21 - 10:07 pm
Lyra Therapeutics
mental health
digital health
Lyra’s LYR-210 Drug Matrix Shows Anti-Inflammatory Effects in Chronic Rhinosinusitis Patients
BioSpace
Mon, 10/5/20 - 10:55 am
Lyra Therapeutics
LYR-210
chronic rhinosinusitis
Trifecta of clinical stage biotechs unveil IPO plans, braving Wall Street's coronavirus panic
Endpoints
Mon, 03/9/20 - 10:48 am
coronaviruses
COVID-19
IPOs
Zentalis Pharmaceuticals
Lyra Therapeutics
Ayala Pharmaceuticals
ENT Focused Lyra Therapeutics Banks $29.5 Million Series B Round
CP Wire
Wed, 09/26/18 - 12:17 pm
Lyra Therapeutics
LYR-210
ENT Focused Lyra Therapeutics Banks $29.5 Million Series B Round
Wed, 09/26/18 - 09:49 am
Lyra Therapeutics